These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

342 related articles for article (PubMed ID: 23774673)

  • 1. Therapeutic antibody targeting of Notch1 in T-acute lymphoblastic leukemia xenografts.
    Agnusdei V; Minuzzo S; Frasson C; Grassi A; Axelrod F; Satyal S; Gurney A; Hoey T; Seganfreddo E; Basso G; Valtorta S; Moresco RM; Amadori A; Indraccolo S
    Leukemia; 2014 Feb; 28(2):278-88. PubMed ID: 23774673
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A novel Monoclonal Antibody against Notch1 Targets Leukemia-associated Mutant Notch1 and Depletes Therapy Resistant Cancer Stem Cells in Solid Tumors.
    Sharma A; Gadkari RA; Ramakanth SV; Padmanabhan K; Madhumathi DS; Devi L; Appaji L; Aster JC; Rangarajan A; Dighe RR
    Sci Rep; 2015 Jun; 5():11012. PubMed ID: 26046801
    [TBL] [Abstract][Full Text] [Related]  

  • 3. NOTCH1 signaling promotes human T-cell acute lymphoblastic leukemia initiating cell regeneration in supportive niches.
    Ma W; Gutierrez A; Goff DJ; Geron I; Sadarangani A; Jamieson CA; Court AC; Shih AY; Jiang Q; Wu CC; Li K; Smith KM; Crews LA; Gibson NW; Deichaite I; Morris SR; Wei P; Carson DA; Look AT; Jamieson CH
    PLoS One; 2012; 7(6):e39725. PubMed ID: 22768113
    [TBL] [Abstract][Full Text] [Related]  

  • 4. IL-7R is essential for leukemia-initiating cell activity of T-cell acute lymphoblastic leukemia.
    González-García S; Mosquera M; Fuentes P; Palumbo T; Escudero A; Pérez-Martínez A; Ramírez M; Corcoran AE; Toribio ML
    Blood; 2019 Dec; 134(24):2171-2182. PubMed ID: 31530562
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Molecular pathogenesis and targeted therapies for NOTCH1-induced T-cell acute lymphoblastic leukemia.
    Paganin M; Ferrando A
    Blood Rev; 2011 Mar; 25(2):83-90. PubMed ID: 20965628
    [TBL] [Abstract][Full Text] [Related]  

  • 6. DLL4 regulates NOTCH signaling and growth of T acute lymphoblastic leukemia cells in NOD/SCID mice.
    Minuzzo S; Agnusdei V; Pusceddu I; Pinazza M; Moserle L; Masiero M; Rossi E; Crescenzi M; Hoey T; Ponzoni M; Amadori A; Indraccolo S
    Carcinogenesis; 2015 Jan; 36(1):115-21. PubMed ID: 25355291
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Blockade of Oncogenic NOTCH1 with the SERCA Inhibitor CAD204520 in T Cell Acute Lymphoblastic Leukemia.
    Marchesini M; Gherli A; Montanaro A; Patrizi L; Sorrentino C; Pagliaro L; Rompietti C; Kitara S; Heit S; Olesen CE; Møller JV; Savi M; Bocchi L; Vilella R; Rizzi F; Baglione M; Rastelli G; Loiacono C; La Starza R; Mecucci C; Stegmaier K; Aversa F; Stilli D; Lund Winther AM; Sportoletti P; Bublitz M; Dalby-Brown W; Roti G
    Cell Chem Biol; 2020 Jun; 27(6):678-697.e13. PubMed ID: 32386594
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dissecting molecular mechanisms of resistance to NOTCH1-targeted therapy in T-cell acute lymphoblastic leukemia xenografts.
    Agnusdei V; Minuzzo S; Pinazza M; Gasparini A; Pezzè L; Amaro AA; Pasqualini L; Bianco PD; Tognon M; Frasson C; Palumbo P; Ciribilli Y; Pfeffer U; Carella M; Amadori A; Indraccolo S
    Haematologica; 2020 May; 105(5):1317-1328. PubMed ID: 31467126
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Recent advances on NOTCH signaling in T-ALL.
    Tzoneva G; Ferrando AA
    Curr Top Microbiol Immunol; 2012; 360():163-82. PubMed ID: 22673746
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Preclinical analysis of the γ-secretase inhibitor PF-03084014 in combination with glucocorticoids in T-cell acute lymphoblastic leukemia.
    Samon JB; Castillo-Martin M; Hadler M; Ambesi-Impiobato A; Paietta E; Racevskis J; Wiernik PH; Rowe JM; Jakubczak J; Randolph S; Cordon-Cardo C; Ferrando AA
    Mol Cancer Ther; 2012 Jul; 11(7):1565-75. PubMed ID: 22504949
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The impact of NOTCH1, FBW7 and PTEN mutations on prognosis and downstream signaling in pediatric T-cell acute lymphoblastic leukemia: a report from the Children's Oncology Group.
    Larson Gedman A; Chen Q; Kugel Desmoulin S; Ge Y; LaFiura K; Haska CL; Cherian C; Devidas M; Linda SB; Taub JW; Matherly LH
    Leukemia; 2009 Aug; 23(8):1417-25. PubMed ID: 19340001
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Metabolic reprogramming induces resistance to anti-NOTCH1 therapies in T cell acute lymphoblastic leukemia.
    Herranz D; Ambesi-Impiombato A; Sudderth J; Sánchez-Martín M; Belver L; Tosello V; Xu L; Wendorff AA; Castillo M; Haydu JE; Márquez J; Matés JM; Kung AL; Rayport S; Cordon-Cardo C; DeBerardinis RJ; Ferrando AA
    Nat Med; 2015 Oct; 21(10):1182-9. PubMed ID: 26390244
    [TBL] [Abstract][Full Text] [Related]  

  • 13. In vitro validation of gamma-secretase inhibitors alone or in combination with other anti-cancer drugs for the treatment of T-cell acute lymphoblastic leukemia.
    De Keersmaecker K; Lahortiga I; Mentens N; Folens C; Van Neste L; Bekaert S; Vandenberghe P; Odero MD; Marynen P; Cools J
    Haematologica; 2008 Apr; 93(4):533-42. PubMed ID: 18322257
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Proteomics of resistance to Notch1 inhibition in acute lymphoblastic leukemia reveals targetable kinase signatures.
    Franciosa G; Smits JGA; Minuzzo S; Martinez-Val A; Indraccolo S; Olsen JV
    Nat Commun; 2021 May; 12(1):2507. PubMed ID: 33947863
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Characterization of activating mutations of NOTCH3 in T-cell acute lymphoblastic leukemia and anti-leukemic activity of NOTCH3 inhibitory antibodies.
    Bernasconi-Elias P; Hu T; Jenkins D; Firestone B; Gans S; Kurth E; Capodieci P; Deplazes-Lauber J; Petropoulos K; Thiel P; Ponsel D; Hee Choi S; LeMotte P; London A; Goetcshkes M; Nolin E; Jones MD; Slocum K; Kluk MJ; Weinstock DM; Christodoulou A; Weinberg O; Jaehrling J; Ettenberg SA; Buckler A; Blacklow SC; Aster JC; Fryer CJ
    Oncogene; 2016 Nov; 35(47):6077-6086. PubMed ID: 27157619
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Characterization of Notch1 antibodies that inhibit signaling of both normal and mutated Notch1 receptors.
    Aste-Amézaga M; Zhang N; Lineberger JE; Arnold BA; Toner TJ; Gu M; Huang L; Vitelli S; Vo KT; Haytko P; Zhao JZ; Baleydier F; L'Heureux S; Wang H; Gordon WR; Thoryk E; Andrawes MB; Tiyanont K; Stegmaier K; Roti G; Ross KN; Franlin LL; Wang H; Wang F; Chastain M; Bett AJ; Audoly LP; Aster JC; Blacklow SC; Huber HE
    PLoS One; 2010 Feb; 5(2):e9094. PubMed ID: 20161710
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The Genetics and Mechanisms of T-Cell Acute Lymphoblastic Leukemia.
    Gianni F; Belver L; Ferrando A
    Cold Spring Harb Perspect Med; 2020 Mar; 10(3):. PubMed ID: 31570389
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Notch1 inhibition targets the leukemia-initiating cells in a Tal1/Lmo2 mouse model of T-ALL.
    Tatarek J; Cullion K; Ashworth T; Gerstein R; Aster JC; Kelliher MA
    Blood; 2011 Aug; 118(6):1579-90. PubMed ID: 21670468
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Proteasome inhibitors exert cytotoxicity and increase chemosensitivity via transcriptional repression of Notch1 in T-cell acute lymphoblastic leukemia.
    Koyama D; Kikuchi J; Hiraoka N; Wada T; Kurosawa H; Chiba S; Furukawa Y
    Leukemia; 2014 Jun; 28(6):1216-26. PubMed ID: 24301524
    [TBL] [Abstract][Full Text] [Related]  

  • 20. MAFB enhances oncogenic Notch signaling in T cell acute lymphoblastic leukemia.
    Pajcini KV; Xu L; Shao L; Petrovic J; Palasiewicz K; Ohtani Y; Bailis W; Lee C; Wertheim GB; Mani R; Muthusamy N; Li Y; Meijerink JPP; Blacklow SC; Faryabi RB; Cherry S; Pear WS
    Sci Signal; 2017 Nov; 10(505):. PubMed ID: 29138297
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.